CYCN - CIK 0001755237
Cyclerion Therapeutics, Inc. trades as CYCN. In its fiscal 2025 annual report the company posted revenue of $2.07M, up 3.7% from the prior year and net income of -$3.53M. This page tracks Cyclerion Therapeutics, Inc. through 344 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 6 fiscal years Cyclerion Therapeutics, Inc.'s revenue declined from $4.51M to $2.07M, a compound annual decline rate of 12.1%. Net profit margin expanded from -2729.3% to -170.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-12 |
| SCHEDULE 13G | - | 2026-05-07 |
| Annual report (amended) | 10-K/A | 2026-04-30 |
| S-4 | - | 2026-04-20 |
| 425 | - | 2026-04-01 |
| Major company event | 8-K | 2026-04-01 |
| Annual report | 10-K | 2026-03-30 |
| Major company event | 8-K | 2026-02-17 |
The largest companies sharing Cyclerion Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Cyclerion Therapeutics, Inc. reported revenue of $2.07M for fiscal year 2025, an increase of 3.7% year over year.
In its latest fiscal year Cyclerion Therapeutics, Inc. reported a net loss of $3.53M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.